Your data is in. Now comes the part that determines whether it's enough.

The analysis phase feels like the finish line. It isn't. Between locked data and a submission package that satisfies FDA reviewers lies a body of work that requires precision, experience, and an unflinching assessment of what your data actually shows — and what it doesn't.

This is where submissions succeed or stall.

We deliver submission-ready statistical packages that hold up under scrutiny.

BSC supports sponsors through the full arc of submission preparation — from final analysis and programming through CSR statistical sections and submission package QC. Whether you've been with us since the design stage or are bringing us in to carry the work across the finish line, we integrate seamlessly and deliver with the rigor FDA expects.

And when sponsors come to us having already seen their data — and aren't happy with what they see — we do some of our most important work.

When the data isn't telling the story you expected

It happens more often than sponsors want to admit. The primary endpoint missed. A subgroup tells a more complicated story. The effect size is smaller than powered for. Before concluding the program is lost, experienced statistical eyes need to assess what the data actually supports.

BSC helps sponsors navigate this honestly — evaluating what the data can and cannot support, identifying defensible analytical approaches, assessing sensitivity analyses, and determining whether a credible path to submission exists. We don't manufacture outcomes. We find the strongest defensible story the data allows, and we tell it clearly.

This isn't spin. It's rigorous, experienced statistical judgment applied at the moment it matters most.

What we do at this stage

Drawing on our Analyze and Advance services, we support:

• Full statistical analysis of primary, secondary, and exploratory endpoints

• Statistical programming, TLF generation, and QC

• CSR statistical methods and results sections

• Submission package review and de-risking assessment

• Sensitivity analyses and alternative analytical frameworks

• Response to FDA statistical questions post-submission

• Integrated summary support and appendix development

The cost of a weak submission package

A statistically sound trial can still produce a flawed submission. Poorly documented methods, inconsistent TLFs, unsupported conclusions, or analyses that don't align with the pre-specified SAP — any of these invite FDA questions that delay approval and erode reviewer confidence. The sponsors who submit with confidence are the ones who treat the analysis phase with the same rigor they brought to the design.

You've invested too much in this trial to leave the submission to chance.